BG102438A - Medicamentous form - Google Patents

Medicamentous form

Info

Publication number: BG102438A
Authority: BG; Bulgaria
Prior art keywords: medicamentous form; medicamentous; vitromodels; formguarantees; activemedicamentous
Prior art date: 1995-11-21

Application number

BG102438A

Other languages

Bulgarian (bg)

English (en)

Inventor

Ross MACRAE

Janet Smith

Original Assignee

Pfizer Research And Development Company, N.V./S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1998-05-08

Publication date

1999-01-29

1998-05-08 Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.

1999-01-29 Publication of BG102438A publication Critical patent/BG102438A/xx

Links

229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000013270 controlled release Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000945 filler Substances 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
238000010874 in vitro model Methods 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG102438A 1995-11-21 1998-05-08 Medicamentous form BG102438A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
BG102438A true BG102438A (en)	1999-01-29

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102438A BG102438A (en)	1995-11-21	1998-05-08	Medicamentous form

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (cs)
JP (1)	JPH10513481A (cs)
KR (1)	KR19990071505A (cs)
CN (1)	CN1215993A (cs)
AP (1)	AP718A (cs)
AR (1)	AR004335A1 (cs)
AU (1)	AU709560B2 (cs)
BG (1)	BG102438A (cs)
BR (1)	BR9611626A (cs)
CA (1)	CA2232715A1 (cs)
CO (1)	CO4480020A1 (cs)
CZ (1)	CZ155498A3 (cs)
GB (1)	GB9523752D0 (cs)
HR (1)	HRP960554A2 (cs)
HU (1)	HUP9903734A3 (cs)
IS (1)	IS4706A (cs)
MA (1)	MA26410A1 (cs)
MX (1)	MX9804008A (cs)
NO (1)	NO982302L (cs)
NZ (1)	NZ322053A (cs)
OA (1)	OA10687A (cs)
PE (1)	PE22898A1 (cs)
PL (1)	PL326981A1 (cs)
SK (1)	SK63098A3 (cs)
TN (1)	TNSN96141A1 (cs)
TR (1)	TR199800902T2 (cs)
WO (1)	WO1997018814A1 (cs)
YU (1)	YU62096A (cs)
ZA (1)	ZA969722B (cs)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
BR9813699A (pt) *	1997-12-16	2000-10-10	Pfizer Prod Inc	Combinação eficaz para o tratamento da impotência
WO1999047128A1 (en)	1998-03-19	1999-09-23	Bristol-Myers Squibb Company	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) *	1998-05-15	2000-10-14	Pfizer	Formulaciones farmaceuticas.
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) *	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) *	2003-10-17	2006-07-19	Ranbaxy Laboratories, Ltd.	Oral matrix formulations of doxazosin
WO2005107702A2 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) *	2004-05-28	2006-04-27	한미약품 주식회사	니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) *	2004-11-20	2007-02-07	대우약품공업주식회사	독사조신을 포함하는 서방성 정제
RU2442574C2 (ru) *	2005-08-22	2012-02-20	Новартис Аг	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
ES2396051T3 (es)	2006-04-26	2013-02-18	Supernus Pharmaceuticals, Inc.	Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
BRPI0711558A2 (pt)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polimorfos
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN100396282C (zh) *	2006-07-25	2008-06-25	山东省医药工业研究所	甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en)	2008-03-11	2009-09-17	Depomed Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
MX339194B (es)	2009-02-13	2016-05-16	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
AU2010239311B2 (en)	2009-04-20	2014-05-22	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
MX341025B (es)	2010-05-05	2016-08-04	Boehringer Ingelheim Int Gmbh *	Terapia de combinacion.
RU2596787C2 (ru)	2010-07-09	2016-09-10	БиЭйчВи ФАРМА, ИНК.	Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
BR112013009635A2 (pt)	2010-10-19	2016-07-12	Elcelyx Therapeutics Inc	terapias à base de ligante de receptor quimiossensorial
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
WO2012094636A2 (en)	2011-01-07	2012-07-12	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
CN102058555A (zh) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	一种多沙唑嗪控释片
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	甲磺酸多沙唑嗪缓释片及其制备方法
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
AU2012345659B2 (en)	2011-12-02	2017-09-28	Synchroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014197744A1 (en)	2013-06-05	2014-12-11	Synchroneuron, Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
CN105616378A (zh) *	2014-10-31	2016-06-01	康普药业股份有限公司	一种氟康唑胶囊及其制备方法
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (it) *	1982-07-06	1988-12-21	Lepetit Spa	Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
IE62597B1 (en) *	1990-07-23	1995-02-08	Alza Corp	Oral osmotic device for delivering nicotine

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Ceased
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Ceased
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP9903734A3 (en)	2000-04-28
NO982302D0 (no)	1998-05-20
AU709560B2 (en)	1999-09-02
CN1215993A (zh)	1999-05-05
HRP960554A2 (en)	1998-02-28
NO982302L (no)	1998-07-17
PE22898A1 (es)	1998-05-07
NZ322053A (en)	1999-11-29
AP718A (en)	1999-01-06
GB9523752D0 (en)	1996-01-24
IS4706A (is)	1998-03-31
HUP9903734A2 (hu)	2000-03-28
SK63098A3 (en)	1999-05-07
WO1997018814A1 (en)	1997-05-29
BR9611626A (pt)	1999-06-01
ZA969722B (en)	1998-05-20
AR004335A1 (es)	1998-11-04
MX9804008A (es)	1998-09-30
CA2232715A1 (en)	1997-05-29
TR199800902T2 (xx)	1998-09-21
PL326981A1 (en)	1998-11-09
OA10687A (en)	2002-11-27
CO4480020A1 (es)	1997-07-09
AP9600883A0 (en)	1997-01-31
EP0862437A1 (en)	1998-09-09
JPH10513481A (ja)	1998-12-22
YU62096A (sh)	1999-03-04
TNSN96141A1 (fr)	2005-03-15
AU7572196A (en)	1997-06-11
MA26410A1 (fr)	2004-12-20
CZ155498A3 (cs)	1999-03-17
KR19990071505A (ko)	1999-09-27

Publication	Publication Date	Title
WO1996039156A3 (en)	1997-03-27	Phosphate-binding polymers for oral administration
TR199800902T2 (xx)	1998-09-21	Ecza form�lasyonlar�.
DE69432559D1 (de)	2003-05-28	Verwendung von eisenbindenden polymeren zur herstellung eines medikaments zur oralen verabreichung
CA2169356A1 (en)	1995-02-23	Phosphate-binding polymers for oral administration
AU1477697A (en)	1997-08-28	Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
WO1997038679A3 (en)	1997-12-04	Fast disintegrating oral dosage form
AU5286696A (en)	1996-10-23	Controlled release biodegradable micro- and nanospheres containing cyclosporin
CA2232356A1 (en)	1997-05-01	Method of producing multi-layer medicaments in solid form for oral or rectal administration
BG104620A (en)	2001-04-30	Oral pharmaceutical extended release dosage form
EP2233155A3 (en)	2011-01-12	Therapeutic polyanhydride compounds for drug delivery
BR9706897A (pt)	1999-08-31	Composições antifúngicas com biodisponibilidade aperfeiçoada.
DE60021604D1 (de)	2005-09-01	Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
ATE290015T1 (de)	2005-03-15	Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
AU3438897A (en)	1998-01-21	Stable drug form for oral administration and process for the preparation thereof
GEP20033014B (en)	2003-07-25	Enteric Coated Pharmaceutical Composition and Method of Manufacturing
CA2212309A1 (en)	1996-08-08	Extended-release solid oral dosage forms of drugs having low solubility in water
NO992477D0 (no)	1999-05-21	Sugetablett med modifisert frigj°ring av virkestoffer i gastrointestinalsystemet
EP1992338A3 (en)	2009-08-12	Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
ATE94401T1 (de)	1993-10-15	Physiologisch wirkende substanzen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen davon.
WO2003063823A3 (en)	2003-12-04	Osmotic delivery system
GEP20063719B (en)	2006-01-10	Prevention of Migraine Recurrence
BG105216A (en)	2001-10-31	Use of camptothecin derivatives , with reduced gastrointestinal toxicity
CA2209868A1 (en)	1999-02-15	Pharmaceutical compositions comprising cefuroxime axetil
CA2209673A1 (en)	1996-07-18	Solid medicament form with active agent distributed in polymer material
GB9420748D0 (en)	1994-11-30	1,5 benzodiazepine derivatives